SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a monoclonal antibody that targets the CSF‑1 receptor to deplete tumor-associated macrophages in Tenosynovial Giant Cell Tumour (TGCT). The company has initiated the TANGENT Phase 3 trial — a global, multi-center, randomized, double-blind, placebo-controlled study planned for about 130 patients — and has dosed its first patients. Early clinical data reported an overall response rate (ORR) of approximately 71%. SynOx is also exploring emactuzumab’s potential in other macrophage-driven disorders, including graft‑versus‑host disease. The recent $92M Series B financing will support the Phase 3 program and further development. SynOx has raised $323.8M to date, was founded in 2020, and operates from Dublin with a presence in Oxford; the company reports 11–50 employees. SynOx Therapeutics is a late-stage clinical biopharmaceutical company developing emactuzumab, a monoclonal antibody that inhibits CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1–related and macrophage-driven diseases. The company is executing TANGENT, a registrational Phase 3 study of emactuzumab. Management, led by CEO Ray Barlow, aims to establish emactuzumab as a best-in-class drug to address unmet medical needs and improve patient quality of life. SynOx is headquartered in Dublin, Ireland and Oxford, UK. Financially, the company recently supplemented its balance sheet with a debt facility after completing a $75M Series B, positioning it to fund ongoing clinical development. The new financing is intended to support completion and advancement of the registrational program. SynOx Therapeutics is a clinical-stage biopharmaceutical spin-out from Celleron Therapeutics focused on developing emactuzumab, a humanized IgG1 CSF‑1R targeted antibody. Emactuzumab is designed to deplete tumour-associated macrophages and has shown a favorable safety profile and encouraging efficacy in diffuse tenosynovial giant cell tumours (TGCT). The company secured exclusive worldwide rights for the clinical development, manufacturing and commercialization of emactuzumab under a license agreement with Roche. SynOx announced a €37M Series A financing to fund continued development in TGCT and other indications. Management says it will focus on generating the data necessary to register the therapy in a time- and cost-efficient way. The team combines biotech and pharma experience and the board includes investor representatives alongside Celleron’s chairman and SynOx’s CEO.

Total raised

$171M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2024